vs
MESA LABORATORIES INC（MLAB）与Porch Group, Inc.（PRCH）财务数据对比。点击上方公司名可切换其他公司
Porch Group, Inc.的季度营收约是MESA LABORATORIES INC的1.9倍（$121.1M vs $65.1M），MESA LABORATORIES INC净利率更高（5.6% vs -3.9%，领先9.5%），Porch Group, Inc.同比增速更快（100.0% vs 3.6%），过去两年Porch Group, Inc.的营收复合增速更高（26.4% vs 5.1%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
Porch Group是一家面向屋主的家居改造服务平台，致力于连接屋主与当地的家居装修承包商。平台不仅提供超过160种家居装修项目的在线预约服务，还涵盖专业建议文章与装修成本指南，帮助屋主便捷规划各类家装工程。
MLAB vs PRCH — 直观对比
营收规模更大
PRCH
是对方的1.9倍
$65.1M
营收增速更快
PRCH
高出96.4%
3.6%
净利率更高
MLAB
高出9.5%
-3.9%
两年增速更快
PRCH
近两年复合增速
5.1%
损益表 — Q3 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $121.1M |
| 净利润 | $3.6M | $-4.7M |
| 毛利率 | 64.2% | 52.7% |
| 营业利润率 | 12.2% | 34.7% |
| 净利率 | 5.6% | -3.9% |
| 营收同比 | 3.6% | 100.0% |
| 净利润同比 | 316.6% | 2.0% |
| 每股收益（稀释后） | $0.65 | $-0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABPRCH
| Q1 26 | — | $121.1M | ||
| Q4 25 | $65.1M | $112.3M | ||
| Q3 25 | $60.7M | $115.1M | ||
| Q2 25 | $59.5M | $107.0M | ||
| Q1 25 | $62.1M | $84.5M | ||
| Q4 24 | $62.8M | $75.3M | ||
| Q3 24 | $57.8M | $77.7M | ||
| Q2 24 | $58.2M | $75.9M |
净利润MLABPRCH
| Q1 26 | — | $-4.7M | ||
| Q4 25 | $3.6M | $-3.5M | ||
| Q3 25 | $2.5M | $-10.9M | ||
| Q2 25 | $4.7M | $2.6M | ||
| Q1 25 | $-7.1M | $8.4M | ||
| Q4 24 | $-1.7M | $30.5M | ||
| Q3 24 | $3.4M | $14.4M | ||
| Q2 24 | $3.4M | $-64.3M |
毛利率MLABPRCH
| Q1 26 | — | 52.7% | ||
| Q4 25 | 64.2% | 99.5% | ||
| Q3 25 | 61.5% | 75.6% | ||
| Q2 25 | 62.0% | 70.9% | ||
| Q1 25 | 61.8% | 77.4% | ||
| Q4 24 | 63.3% | — | ||
| Q3 24 | 61.3% | 79.4% | ||
| Q2 24 | 64.0% | 22.1% |
营业利润率MLABPRCH
| Q1 26 | — | 34.7% | ||
| Q4 25 | 12.2% | 14.7% | ||
| Q3 25 | 7.8% | 14.2% | ||
| Q2 25 | 5.1% | 4.7% | ||
| Q1 25 | 2.4% | -1.5% | ||
| Q4 24 | 9.2% | 33.3% | ||
| Q3 24 | 6.1% | -3.2% | ||
| Q2 24 | 9.6% | -69.2% |
净利率MLABPRCH
| Q1 26 | — | -3.9% | ||
| Q4 25 | 5.6% | -3.1% | ||
| Q3 25 | 4.1% | -9.4% | ||
| Q2 25 | 8.0% | 2.4% | ||
| Q1 25 | -11.4% | 9.9% | ||
| Q4 24 | -2.7% | 40.5% | ||
| Q3 24 | 5.9% | 18.5% | ||
| Q2 24 | 5.8% | -84.8% |
每股收益（稀释后）MLABPRCH
| Q1 26 | — | $-0.04 | ||
| Q4 25 | $0.65 | $0.00 | ||
| Q3 25 | $0.45 | $-0.10 | ||
| Q2 25 | $0.85 | $0.00 | ||
| Q1 25 | $-1.30 | $0.07 | ||
| Q4 24 | $-0.31 | $0.34 | ||
| Q3 24 | $0.63 | $0.12 | ||
| Q2 24 | $0.62 | $-0.65 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $68.4M |
| 总债务越低越好 | $68.4M | $391.3M |
| 股东权益账面价值 | $186.7M | $26.3M |
| 总资产 | $434.8M | $806.6M |
| 负债/权益比越低杠杆越低 | 0.37× | 14.87× |
8季度趋势，按日历期对齐
现金及短期投资MLABPRCH
| Q1 26 | — | $68.4M | ||
| Q4 25 | $29.0M | $57.3M | ||
| Q3 25 | $20.4M | $85.0M | ||
| Q2 25 | $21.3M | $79.8M | ||
| Q1 25 | $27.3M | $70.4M | ||
| Q4 24 | $27.3M | $191.7M | ||
| Q3 24 | $24.3M | $238.6M | ||
| Q2 24 | $28.5M | $308.4M |
总债务MLABPRCH
| Q1 26 | — | $391.3M | ||
| Q4 25 | $68.4M | $392.8M | ||
| Q3 25 | $69.4M | $387.1M | ||
| Q2 25 | $70.3M | $394.1M | ||
| Q1 25 | $71.3M | $409.2M | ||
| Q4 24 | $72.2M | $403.9M | ||
| Q3 24 | $73.1M | $399.0M | ||
| Q2 24 | $74.1M | $436.8M |
股东权益MLABPRCH
| Q1 26 | — | $26.3M | ||
| Q4 25 | $186.7M | $-24.6M | ||
| Q3 25 | $178.5M | $-27.9M | ||
| Q2 25 | $172.5M | $-29.3M | ||
| Q1 25 | $159.8M | $-52.4M | ||
| Q4 24 | $155.2M | $-43.2M | ||
| Q3 24 | $161.5M | $-77.0M | ||
| Q2 24 | $150.7M | $-101.9M |
总资产MLABPRCH
| Q1 26 | — | $806.6M | ||
| Q4 25 | $434.8M | $797.4M | ||
| Q3 25 | $430.4M | $787.7M | ||
| Q2 25 | $435.7M | $770.7M | ||
| Q1 25 | $433.3M | $802.3M | ||
| Q4 24 | $433.3M | $814.0M | ||
| Q3 24 | $454.1M | $867.3M | ||
| Q2 24 | $440.4M | $876.1M |
负债/权益比MLABPRCH
| Q1 26 | — | 14.87× | ||
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | — |
| 自由现金流经营现金流 - 资本支出 | $18.0M | — |
| 自由现金流率自由现金流/营收 | 27.7% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | 5.17× | — |
| 过去12个月自由现金流最近4个季度 | $37.9M | — |
8季度趋势，按日历期对齐
经营现金流MLABPRCH
| Q1 26 | — | — | ||
| Q4 25 | $18.8M | $1.2M | ||
| Q3 25 | $8.2M | $40.8M | ||
| Q2 25 | $1.9M | $35.6M | ||
| Q1 25 | $12.7M | $-11.2M | ||
| Q4 24 | $18.1M | $-26.6M | ||
| Q3 24 | $5.3M | $12.4M | ||
| Q2 24 | $10.7M | $-26.0M |
自由现金流MLABPRCH
| Q1 26 | — | — | ||
| Q4 25 | $18.0M | $1.1M | ||
| Q3 25 | $7.1M | $40.7M | ||
| Q2 25 | $884.0K | $35.4M | ||
| Q1 25 | $11.9M | $-11.2M | ||
| Q4 24 | $17.3M | $-26.8M | ||
| Q3 24 | $3.5M | $12.2M | ||
| Q2 24 | $9.9M | $-26.0M |
自由现金流率MLABPRCH
| Q1 26 | — | — | ||
| Q4 25 | 27.7% | 1.0% | ||
| Q3 25 | 11.7% | 35.4% | ||
| Q2 25 | 1.5% | 33.0% | ||
| Q1 25 | 19.2% | -13.3% | ||
| Q4 24 | 27.6% | -35.6% | ||
| Q3 24 | 6.0% | 15.7% | ||
| Q2 24 | 16.9% | -34.3% |
资本支出强度MLABPRCH
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | 0.1% | ||
| Q3 25 | 1.8% | 0.1% | ||
| Q2 25 | 1.7% | 0.2% | ||
| Q1 25 | 1.2% | 0.1% | ||
| Q4 24 | 1.3% | 0.3% | ||
| Q3 24 | 3.1% | 0.3% | ||
| Q2 24 | 1.5% | 0.1% |
现金转化率MLABPRCH
| Q1 26 | — | — | ||
| Q4 25 | 5.17× | — | ||
| Q3 25 | 3.32× | — | ||
| Q2 25 | 0.40× | 13.79× | ||
| Q1 25 | — | -1.33× | ||
| Q4 24 | — | -0.87× | ||
| Q3 24 | 1.54× | 0.86× | ||
| Q2 24 | 3.17× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
PRCH
暂无分部数据
